SAAKSHI
Saakshi Medtech financials
- Market cap
- ₹610 Cr
- Sector
- Capital Goods
- Calls analysed
- 1
Saakshi Medtech H1 FY26
What went well
- Revenue from operations increased by approximately 31% year-on-year, reaching Rs. 58.31 crores in H1 FY26.
- EBITDA improved significantly to 18.71%, reflecting effective cost control and operational optimization.
- The aerospace sector demonstrated exceptional growth, with revenue increasing nearly seven-fold to over Rs. 1 crore in H1 FY26 compared to H1 FY25.
What to watch
- Cash and cash equivalents declined from Rs. 3.26 crores to Rs. 1.59 crores due to CAPEX and working capital requirements.
- Inventory and receivables are noted to be 'a bit on higher side' compared to the previous year, requiring management attention.
Guidance record · Q2 FY26
what the last two calls moved 7 tracked 0 delivered 0 missed 7 open- FY26 Revenue open said Q2 FY26 Promised: Rs. 140-150 crores Q2 FY26: Management confirmed they expect to reach somewhere close to the Rs. 140-150 Cr target.
All 7 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q4 FY26: revenue down 6.6%, net profit up 0.0% against the same quarter last year.
| Line item | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 69 | 61 | 61 | 44 | 48 −30% | 58 −5% | 57 −7% |
| EBITDA | 12 | 10 | 10 | 6 | 4 −67% | 11 +10% | 12 +20% |
| Net profit | 7 | 6 | 6 | 3 | 1 −86% | 7 +17% | 6 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +90.5% 1Y
1Y: ₹181.35 on 10 Sept 2025 → ₹345.4. High ₹350.4 (10 Sept 2026), low ₹151.7 (27 Oct 2025).
How the price took the results
close before → close after
- Q2 FY26
- −2.0%
- 28 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr |
| Reserves | ₹18 Cr | ₹27 Cr | ₹40 Cr | ₹76 Cr | ₹87 Cr | ₹93 Cr |
| Borrowings | ₹22 Cr | ₹16 Cr | ₹20 Cr | ₹18 Cr | ₹24 Cr | ₹25 Cr |
| Other liabilities | ₹14 Cr | ₹19 Cr | ₹31 Cr | ₹19 Cr | ₹19 Cr | ₹21 Cr |
| Total liabilities | ₹56 Cr | ₹65 Cr | ₹93 Cr | ₹131 Cr | ₹148 Cr | ₹157 Cr |
| Fixed assets | ₹22 Cr | ₹26 Cr | ₹34 Cr | ₹62 Cr | ₹76 Cr | ₹83 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹9 Cr | ₹10 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹34 Cr | ₹39 Cr | ₹59 Cr | ₹68 Cr | ₹62 Cr | ₹64 Cr |
| Total assets | ₹56 Cr | ₹65 Cr | ₹93 Cr | ₹131 Cr | ₹148 Cr | ₹157 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, DIIs trimmed −1.05 pp while promoters added +0.93 pp. The shareholder count shrank 31% to 1,311.
- Promoters
- 74.8%
- FIIs
- 0.1%
- DIIs
- 0.3%
- Public
- 24.8%
Since Sep 2025
- DIIs −1.05 pp
- Promoters +0.93 pp
- Public +0.24 pp
How it drifted, 9 quarters
Over this window the public went from 16.9% to 24.8% — +8.0 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 73.6%, FIIs 3.0%, DIIs 6.5%, Public 16.9%.Mar '24: Promoters 73.6%, FIIs 0.0%, DIIs 1.8%, Public 24.6%.Sep '24: Promoters 73.6%, FIIs 0.1%, DIIs 1.5%, Public 24.7%.Dec '24: Promoters 73.6%, FIIs 0.1%, DIIs 1.5%, Public 24.8%.Mar '25: Promoters 73.6%, FIIs 0.1%, DIIs 1.6%, Public 24.7%.Sep '25: Promoters 73.9%, FIIs 0.2%, DIIs 1.3%, Public 24.6%.Mar '26: Promoters 74.8%, FIIs 0.1%, DIIs 0.3%, Public 24.8%.Jun '26: Promoters 74.8%, FIIs 0.1%, DIIs 0.3%, Public 24.8%.Aug '26: Promoters 74.8%, FIIs 0.1%, DIIs 0.3%, Public 24.8%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Huf newly disclosed 1.29% held
- Pankaj Prasoon +0.45 pp 2.34% held
- Jatinder Agarwal +0.09 pp 4.98% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of Saakshi Medtech above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Chitra Vijay Latkar | 66.27% | unchanged |
| Jatinder Agarwal | 4.98% | +0.09 pp |
| Mayuri Aniket Latkar . | 4.71% | unchanged |
| Aniket Vijay Latkar | 3.84% | unchanged |
| Pankaj Prasoon | 2.34% | +0.45 pp |
| Huf | 1.29% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 23.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse Saakshi Medtech
Guides on how to read this kind of business and the numbers that matter.